Stanford University, BAS/ MS
Massachusetts Institute of Technology, PhD
Harvard Medical School, MD
Stanford University Hospital, Intern
Brigham and Women’s Hospital, Radiation Oncology
Massachusetts General Hospital, Internal Medicine
University of California, San Francisco, Hematology-Oncology Fellowship

Honors & Awards

  • 1997-2000
    Howard Hughes Predoctoral Fellowship
  • 1998
    MIT Graduate Student Teaching Award
  • 2006
    James Tolbert Shipley Prize for Excellence in Research, Harvard Medical School
  • 2013
    AACR-Amgen Clinical and Translational Fellowship
  • 2013-2017
    Damon Runyon Postdoctoral Fellowship
  • 2014, 2015
    Lung Cancer Research Foundation Fellowship
  • 2016
    ASCO-Young Investigator Award
  • 2017
    AACR Scholar-in-Training Travel Award
  • 2017
    ASCO Young Investigator Forum Top Presenter
  • 2022
    ASCO Career Development Award

Selected Publications

  1. Wang VE, Schmidt T, Chen J, Sharp PA, Tantin D. Embryonic lethality, decreasederythropoiesis, and defective octamer-dependent promoter activation inOct-1-deficient mice. Mol Cell Biol. 2004 Feb;24(3):1022-32. PubMed [citation]PMID: 14729950, PMCID: PMC321444
  2. Wang VE, Tantin D, Chen J, Sharp PA. B cell development and immunoglobulintranscription in Oct-1-deficient mice. Proc Natl Acad Sci U S A. 2004 Feb17;101(7):2005-10. Epub 2004 Feb 4. PubMed [citation] PMID: 14762167, PMCID:PMC357042
  3. Shakya A, Cooksey R, Cox JE, Wang V, McClain DA, Tantin D. Oct1 loss of function induces a coordinate metabolic shift that opposes tumorigenicity. Nat Cell Biol. 2009 Mar;11(3):320-7. doi: 10.1038/ncb1840. Epub 2009 Feb 15. PubMed [citation]PMID: 19219035
  4. Magbanua MJ, Pugia M, Lee JS, Jabon M, Wang V, Gubens M, Marfurt K, Pence J,Sidhu H, Uzgiris A, Rugo HS, Park JW. A Novel Strategy for Detection andEnumeration of Circulating Rare Cell Populations in Metastatic Cancer PatientsUsing Automated Microfluidic Filtration and Multiplex Immunoassay. PLoS One. 2015Oct 23;10(10):e0141166. doi: 10.1371/journal.pone.0141166. eCollection 2015.PubMed [citation] PMID: 26496203, PMCID: PMC4619669
  5. Wang VE, Grandis JR, Ko AH. New Strategies in Esophageal Carcinoma: TranslationalInsights from Signaling Pathways and Immune Checkpoints. Clin Cancer Res. 2016Sep 1;22(17):4283-90. doi: 10.1158/1078-0432.CCR-16-0292. Epub 2016 Jul 1.Review. PubMed [citation] PMID: 27370606
  6. Wang V, Bivona T, Ali SM, Schrock AB, Miller VA. CD74-ROS1 Fusion inNSCLC Detected by Hybrid Capture-Based Tissue Genomic Profiling and ctDNA Assays.J Thorac Oncol. 2017 Feb;12(2):e19-e20. doi: 10.1016/j.jtho.2016.11.2217. Noabstract available. PubMed [citation] PMID: 28115114
  7. Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, FoghS, Bergsland EK. A Case of Metastatic Atypical Neuroendocrine Tumor with ALKTranslocation and Diffuse Brain Metastases. Oncologist. 2017 Jul;22(7):768-773.doi: 10.1634/theoncologist.2017-0054. Epub 2017 May 15. PubMed [citation] PMID:28507205, PMCID: PMC5507651
  8. Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, Jablons D.Checkpoint inhibitor is active against large cell neuroendocrine carcinoma withhigh tumor mutation burden. J Immunother Cancer. 2017 Sep 19;5(1):75. doi:10.1186/s40425-017-0281-y. PubMed [citation] PMID: 28923100, PMCID: PMC5604145
  9. Blakely CM, Watkins TBK, Wu W, Gini B, Chabon JJ, McCoach CE, McGranahan N,Wilson GA, Birkbak NJ, Olivas VR, Rotow J, Maynard A, Wang V, Gubens MA, BanksKC, Lanman RB, Caulin AF, St John J, Cordero AR, Giannikopoulos P, Simmons AD,Mack PC, et al. Evolution and clinical impact of co-occurring genetic alterationsin advanced-stage EGFR-mutant lung cancers. Nat Genet. 2017 Dec;49(12):1693-1704.doi: 10.1038/ng.3990. Epub 2017 Nov 6. PubMed [citation] PMID: 29106415, PMCID:PMC5709185
  10. Shah KN, Bhatt R, Rotow J, Rohrberg J, Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, Galeas J, Donnella HJ, Kaushik S, Ku A, Dumont S, Krings G,Haringsma HJ, Robillard L, Simmons AD, Harding TC, McCormick F, Goga A, et al.Aurora kinase A drives the evolution of resistance to third-generation EGFRinhibitors in lung cancer. Nat Med. 2019 Jan;25(1):111-118. doi:10.1038/s41591-018-0264-7. Epub 2018 Nov 26. PubMed [citation] PMID: 30478424,PMCID: PMC6324945
  11. Wang VE, Xue JY, Frederick DT, Cao Y, Lin E, Wilson C, Urisman A, Carbone DP, Flaherty KT, Bernards R, Lito P, Settleman J, McCormick F. Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation. Clin Cancer Res. 2019 Dec 1;25(23):7202-7217. doi: 10.1158/1078-0432.CCR-18-2779. Epub 2019 Sep 12.PMID: 31515463

Go to UCSF Profiles, powered by CTSI